Jonathan Wilde, PhD is the Senior Director of Discovery Research at Emugen Therapeutics, a private biotechnology company based in Woburn, MA that is developing next-generation gene therapies for neurodevelopmental and neurodegenerative diseases.

Dr. Wilde has a Bachelor of Science degree in Biotechnology from The Pennsylvania State University and a PhD in Cell Biology, Stem Cells, and Development from University of Colorado Anschutz Medical Campus, where he identified novel mechanisms regulating vitamin A’s functions during early brain development.

​

During his postdoctoral fellowship with Dr. Guoping Feng at The McGovern Institute for Brain Research at MIT, he developed cutting-edge genome editing approaches and engineered primate and mouse models of neurological disorders.

​

Following his postdoc, Dr. Wilde was a group leader at the McGovern Institute where he continued to improve genome editing approaches and developed tools to assess their safety and efficacy in non-human primates. His multidisciplinary expertise spans the fields of molecular genetics, cellular and molecular neuroscience, developmental biology, and genome editing.

​

Dr. Wilde is a founding scientist at Emugen Therapeutics, having overseen its early-stage research & development since the company’s launch in 2021.